232 related articles for article (PubMed ID: 31836711)
41. Functional analysis of ABCB4 mutations relates clinical outcomes of progressive familial intrahepatic cholestasis type 3 to the degree of MDR3 floppase activity.
Gordo-Gilart R; Andueza S; Hierro L; Martínez-Fernández P; D'Agostino D; Jara P; Alvarez L
Gut; 2015 Jan; 64(1):147-55. PubMed ID: 24594635
[TBL] [Abstract][Full Text] [Related]
42. Molecular Insights of Cholestasis in MDR2 Knockout Murine Liver Organoids.
Blázquez-García I; Guerrero L; Cacho-Navas C; Djouder N; Millan J; Paradela A; Carmona-Rodríguez L; Corrales FJ
J Proteome Res; 2024 Apr; 23(4):1433-1442. PubMed ID: 38488493
[TBL] [Abstract][Full Text] [Related]
43. Familial cholestasis: progressive familial intrahepatic cholestasis, benign recurrent intrahepatic cholestasis and intrahepatic cholestasis of pregnancy.
van der Woerd WL; van Mil SW; Stapelbroek JM; Klomp LW; van de Graaf SF; Houwen RH
Best Pract Res Clin Gastroenterol; 2010 Oct; 24(5):541-53. PubMed ID: 20955958
[TBL] [Abstract][Full Text] [Related]
44. Comment on "Synthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB/c.Abcb4
Weber ND; Martínez-García J; González-Aseguinolaza G
J Hepatol; 2022 Mar; 76(3):749-751. PubMed ID: 34626730
[No Abstract] [Full Text] [Related]
45. Reversal of advanced fibrosis after long-term ursodeoxycholic acid therapy in a patient with residual expression of MDR3.
Frider B; Castillo A; Gordo-Gilart R; Bruno A; Amante M; Alvarez L; Mathet V
Ann Hepatol; 2015; 14(5):745-51. PubMed ID: 26256905
[TBL] [Abstract][Full Text] [Related]
46. Case series of progressive familial intrahepatic cholestasis type 3: Characterization of variants in
Cheng J; Gong L; Mi X; Wu X; Zheng J; Yang W
Front Med (Lausanne); 2022; 9():962408. PubMed ID: 36569137
[TBL] [Abstract][Full Text] [Related]
47. The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood.
Jacquemin E; De Vree JM; Cresteil D; Sokal EM; Sturm E; Dumont M; Scheffer GL; Paul M; Burdelski M; Bosma PJ; Bernard O; Hadchouel M; Elferink RP
Gastroenterology; 2001 May; 120(6):1448-58. PubMed ID: 11313315
[TBL] [Abstract][Full Text] [Related]
48. Progressive Familial Intrahepatic Cholestasis.
Bull LN; Thompson RJ
Clin Liver Dis; 2018 Nov; 22(4):657-669. PubMed ID: 30266155
[TBL] [Abstract][Full Text] [Related]
49. [Clinical and genetic analysis of a family affected by progressive familial intraphepatic cholestasis type 3].
Deng M; Guo L; Song Y
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2018 Oct; 35(5):686-690. PubMed ID: 30298496
[TBL] [Abstract][Full Text] [Related]
50. Effect of mdr2 mutation with combined tandem disruption of canalicular glycoprotein transporters by cyclosporine A on bile formation in mice.
Elamiri A; Perwaiz S; Tuchweber B; Yousef IM
Pharmacol Res; 2003 Nov; 48(5):467-72. PubMed ID: 12967592
[TBL] [Abstract][Full Text] [Related]
51. Ivacaftor-Mediated Potentiation of ABCB4 Missense Mutations Affecting Critical Motifs of the NBDs: Repositioning Perspectives for Hepatobiliary Diseases.
Delaunay JL; Elbahnsi A; Bruneau A; Madry C; Durand-Schneider AM; Stary A; Housset C; Gautheron J; Callebaut I; Aït-Slimane T
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674751
[TBL] [Abstract][Full Text] [Related]
52. [Childhood cholestasis and bile transporters].
Hierro L; Jara P
Gastroenterol Hepatol; 2005; 28(7):388-95. PubMed ID: 16137474
[TBL] [Abstract][Full Text] [Related]
53. ABCB4 Mutations in Adults Cause a Spectrum Cholestatic Disorder Histologically Distinct from Other Biliary Disease.
Sinha A; Bhuva M; Grant C; Gimson AE; Thompson E; Duckworth A; Davies SE; Aithal G; Griffiths WJ
Dig Dis Sci; 2022 Dec; 67(12):5551-5561. PubMed ID: 35288833
[TBL] [Abstract][Full Text] [Related]
54. Carriers of ABCB4 gene variants show a mild clinical course, but impaired quality of life and limited risk for cholangiocarcinoma.
de Vries E; Mazzetti M; Takkenberg B; Mostafavi N; Bikker H; Marzioni M; de Veer R; van der Meer A; Doukas M; Verheij J; Beuers U
Liver Int; 2020 Dec; 40(12):3042-3050. PubMed ID: 32893960
[TBL] [Abstract][Full Text] [Related]
55. MRCK-Alpha and Its Effector Myosin II Regulatory Light Chain Bind ABCB4 and Regulate Its Membrane Expression.
Bruneau A; Delaunay JL; Durand-Schneider AM; Vauthier V; Ben Saad A; Aoudjehane L; El Mourabit H; Morichon R; Falguières T; Gautheron J; Housset C; Aït-Slimane T
Cells; 2022 Feb; 11(4):. PubMed ID: 35203270
[TBL] [Abstract][Full Text] [Related]
56. The mechanism of biliary lipid secretion and its defects.
Elferink RP; Groen AK
Gastroenterol Clin North Am; 1999 Mar; 28(1):59-74, vi. PubMed ID: 10198778
[TBL] [Abstract][Full Text] [Related]
57. Role of multidrug resistance 3 deficiency in pediatric and adult liver disease: one gene for three diseases.
Jacquemin E
Semin Liver Dis; 2001 Nov; 21(4):551-62. PubMed ID: 11745043
[TBL] [Abstract][Full Text] [Related]
58. Rescue of infant progressive familial intrahepatic cholestasis type 3 mice by repeated dosing of AAV gene therapy.
Weber ND; Odriozola L; Ros-Gañán I; García-Porrero G; Salas D; Argemi J; Combal JP; Kishimoto TK; González-Aseguinolaza G
JHEP Rep; 2023 May; 5(5):100713. PubMed ID: 37096142
[TBL] [Abstract][Full Text] [Related]
59. Clinical utility gene card for: progressive familial intrahepatic cholestasis type 3.
Gonzales E; Spraul A; Jacquemin E
Eur J Hum Genet; 2014 Apr; 22(4):. PubMed ID: 24002166
[No Abstract] [Full Text] [Related]
60. Partial external biliary diversion in bile salt export pump deficiency: Association between outcome and mutation.
Ellinger P; Stindt J; Dröge C; Sattler K; Stross C; Kluge S; Herebian D; Smits SHJ; Burdelski M; Schulz-Jürgensen S; Ballauff A; Schulte Am Esch J; Mayatepek E; Häussinger D; Kubitz R; Schmitt L
World J Gastroenterol; 2017 Aug; 23(29):5295-5303. PubMed ID: 28839429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
